[go: up one dir, main page]

PE20120563A1 - Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv - Google Patents

Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv

Info

Publication number
PE20120563A1
PE20120563A1 PE2011002154A PE2011002154A PE20120563A1 PE 20120563 A1 PE20120563 A1 PE 20120563A1 PE 2011002154 A PE2011002154 A PE 2011002154A PE 2011002154 A PE2011002154 A PE 2011002154A PE 20120563 A1 PE20120563 A1 PE 20120563A1
Authority
PE
Peru
Prior art keywords
hpv
papilloma virus
polypeptide
human papilloma
prevention
Prior art date
Application number
PE2011002154A
Other languages
English (en)
Inventor
Guy Jean Marie Fernand Pierre Baudoux
Brigitte Desiree Alberte Colau
Najoua Dendouga
Sandra Giannini
Nicolas Pierre Fernand Lecrenier
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PE20120563A1 publication Critical patent/PE20120563A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE REFIERE A UN POLIPEPTIDO L1 DEL VIRUS DE PAPILOMA HUMANO (HPV) TIPO 18 O FRAGMENTO DEL MISMO QUE COMPRENDE UN EPITOPO DE UN POLIPEPTIDO L2 INSERTADO DENTRO DEL POLIPEPTIDO HPV L1 QUE TIENE UNA SUPRESION EN EL EXTREMO C DE UNO O MAS AMINOACIDOS, EN DONDE UN PRIMER PEPTIDO L2 SE INSERTA EN EL LAZO DE Y UN SEGUNDO PEPTIDO L2 SE INSERTA EN EL EXTREMO C DEL POLIPEPTIDO L1; DONDE DICHO PEPTIDO L2 CONSISTE EN LOS AMINOACIDOS 17 A 36 DE L2 DE HPV TIPO 33 O EN LOS AMINOACIDOS 56 A 75 DE L2 DE HPV TIPO 58. TAMBIEN SE REFIERE A UNA COMPOSICION INMUNOGENICA QUE CONTIENE EL POLIPEPTIDO L1 EN UNA CANTIDAD DE 10 A 50 MICROGRAMOS POR DOSIS HUMANA Y ES UTIL EN LA PREVENCION O TRATAMIENTO DE LA INFECCION POR VIRUS DE PAPILOMA HUMANO (HPV)
PE2011002154A 2009-06-25 2010-06-24 Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv PE20120563A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22035809P 2009-06-25 2009-06-25
US23988009P 2009-09-04 2009-09-04
US32210210P 2010-04-08 2010-04-08

Publications (1)

Publication Number Publication Date
PE20120563A1 true PE20120563A1 (es) 2012-05-17

Family

ID=43014491

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011002154A PE20120563A1 (es) 2009-06-25 2010-06-24 Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv

Country Status (20)

Country Link
US (1) US20120087937A1 (es)
EP (1) EP2445525A2 (es)
JP (1) JP2012530505A (es)
KR (1) KR20120098580A (es)
CN (1) CN102497880A (es)
AU (1) AU2010264695A1 (es)
BR (1) BRPI1014718A2 (es)
CA (1) CA2768172A1 (es)
CL (1) CL2011003271A1 (es)
CO (1) CO6480995A2 (es)
CR (1) CR20120026A (es)
DO (1) DOP2011000396A (es)
EA (1) EA022213B1 (es)
IL (1) IL217094A0 (es)
MA (1) MA33440B1 (es)
MX (1) MX2011013744A (es)
PE (1) PE20120563A1 (es)
SG (1) SG177269A1 (es)
WO (1) WO2010149752A2 (es)
ZA (1) ZA201109453B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102458440A (zh) * 2009-04-10 2012-05-16 约翰·霍普金斯大学 作为广谱人类乳头状瘤病毒(hpv)疫苗的乳头状瘤病毒样颗粒(vlp)
BR112014012491A2 (pt) * 2011-12-01 2017-06-06 Univ Cape Town partícula tipo vírus, método para produzir uma partícula tipo vírus, método para impedir ou tratar a infecção pelo hpv ou câncer cervical em um indivíduo, uso de uma partícula tipo vírus, e, composição farmacêutica
BR112014023092A8 (pt) 2012-03-18 2017-07-25 Glaxosmithkline Biologicals Sa Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit
CN103864936B (zh) * 2012-12-11 2018-01-23 中国疾病预防控制中心病毒病预防控制所 Hpv18型l2ne7e6融合蛋白基因、表达载体、方法、菌株和用途
JPWO2014103608A1 (ja) * 2012-12-25 2017-01-12 一般財団法人化学及血清療法研究所 ＨＰＶ／ＨＢｓキメラタンパク質を有効成分とするＨＰＶ感染症及び／又はＢ型肝炎用ワクチン
CN117187262A (zh) * 2014-02-18 2023-12-08 上海泽润生物科技有限公司 重组人乳头瘤病毒蛋白表达
CN104531741B (zh) * 2014-08-22 2016-08-24 天津康希诺生物技术有限公司 增强hpv抗原表位肽免疫原性的方法及类病毒颗粒、颗粒制备方法与应用
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
EP3209676A4 (en) * 2014-10-24 2018-03-28 Hpvvax, Llc Cancer and skin lesion treatment
DK3368068T3 (da) 2015-10-30 2021-02-22 Univ Copenhagen Viruslignende partikler med effektiv epitopdisplay
KR102351259B1 (ko) * 2015-12-04 2022-01-14 시아먼 유니버시티 58형 인유두종 바이러스 엘1 단백질의 돌연변이체
HK1256935A1 (zh) * 2016-02-27 2019-10-04 哈普威克斯有限责任公司 使用疫苗治療癌症或皮膚病變的方法和組合物
CN107188966B (zh) * 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途
CN107188967B (zh) * 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途
JP7224332B2 (ja) * 2017-07-14 2023-02-17 シャアメン ユニバーシティ ヒトパピローマウイルス１６型のｌ１タンパク質の変異体
BR112020024699A2 (pt) * 2018-06-04 2021-03-09 Xiamen University Mutante da proteína l1 do papilomavírus humano tipo 18
JP7290258B2 (ja) * 2018-09-26 2023-06-13 厦▲門▼大学 ヒトパピローマウイルス５１型のｌ１タンパク質の変異型
CN114127099B (zh) * 2019-07-19 2024-04-19 神州细胞工程有限公司 嵌合的人乳头瘤病毒6型l1蛋白
WO2021013079A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒56型l1蛋白
WO2021013077A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒58型l1蛋白
CN111944834A (zh) * 2020-09-04 2020-11-17 吉林医药学院 人乳头瘤病毒16型表位嵌合l1的重组载体、重组蛋白、病毒样颗粒及其制备和应用
CN112300290B (zh) * 2020-09-30 2022-04-01 北京康乐卫士生物技术股份有限公司 一种使用乳头瘤病毒类病毒颗粒递呈抗原的新型冠状病毒多肽疫苗
CN114716560B (zh) * 2021-01-04 2024-02-02 中国医学科学院基础医学研究所 一种人乳头瘤病毒18型嵌合蛋白及其用途
CN114716562B (zh) * 2021-01-04 2023-11-10 中国医学科学院基础医学研究所 一种人乳头瘤病毒58型嵌合蛋白及其用途
CN114716561B (zh) * 2021-01-04 2024-03-12 中国医学科学院基础医学研究所 一种人乳头瘤病毒31型嵌合蛋白及其用途
CN117285618A (zh) * 2023-08-25 2023-12-26 黑龙江省安碧捷生物科技有限责任公司 一种抗人乳头瘤病毒IgY抗体的制备方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US7351533B2 (en) 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
WO1999013056A1 (en) 1997-09-05 1999-03-18 Medimmune, Inc. IN VITRO METHOD FOR DISASSEMBLY/REASSEMBLY OF PAPILLOMAVIRUS VIRUS-LIKE PARTICLES (VLPs)
CA2302146C (en) 1997-09-16 2010-07-13 Innogenetics N.V. Detection and identification of human papillomavirus by pcr and type-specific reverse hybridization
SI1126876T1 (sl) 1998-10-16 2007-08-31 Glaxosmithkline Biolog Sa Adjuvantni sistemi in vakcine
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
WO2003014402A2 (en) 2001-08-08 2003-02-20 Glaxosmithkline Biologicals S.A. Method for identification of type specific polynucleotide sequences
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
ATE424409T1 (de) * 2002-05-17 2009-03-15 Univ Cape Town Chimere human papilloma virus 16 l1 proteine, welche ein l2 peptid enthalten, damit hergestellte virus-ähnliche partikel und methode zur herstellung der partikel
GB0228715D0 (en) 2002-12-09 2003-01-15 Glaxosmithkline Biolog Sa Vaccine
CN101193653B (zh) 2005-02-01 2013-03-27 美国政府健康及人类服务部 用于诱导广泛交叉中和抗体的乳头瘤病毒l2 n末端肽
JP4825958B2 (ja) * 2005-08-10 2011-11-30 財団法人ヒューマンサイエンス振興財団 高リスク群ヒトパピローマウイルスの中和抗体を誘導する抗原
AU2008268014B2 (en) * 2007-06-26 2013-10-31 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Vaccine antigen capable of inducing cross-reacting and neutralizing antibody against high-risk-type human papillomavirus
WO2009059325A2 (en) * 2007-11-02 2009-05-07 The Johns Hopkins University Multitype hpv peptide compositions and methods for treatment or prevention of human papillomavirus infection
ES2519490T3 (es) 2008-07-31 2014-11-07 Glaxosmithkline Biologicals S.A. Vacuna contra HPV

Also Published As

Publication number Publication date
CR20120026A (es) 2012-04-13
EP2445525A2 (en) 2012-05-02
WO2010149752A2 (en) 2010-12-29
CL2011003271A1 (es) 2012-08-31
EA201190327A1 (ru) 2012-07-30
WO2010149752A3 (en) 2011-03-31
AU2010264695A1 (en) 2012-01-19
US20120087937A1 (en) 2012-04-12
IL217094A0 (en) 2012-02-29
MA33440B1 (fr) 2012-07-03
CO6480995A2 (es) 2012-07-16
JP2012530505A (ja) 2012-12-06
BRPI1014718A2 (pt) 2016-04-12
MX2011013744A (es) 2012-09-28
DOP2011000396A (es) 2012-02-15
CA2768172A1 (en) 2010-12-29
CN102497880A (zh) 2012-06-13
ZA201109453B (en) 2012-08-29
EA022213B1 (ru) 2015-11-30
SG177269A1 (en) 2012-02-28
KR20120098580A (ko) 2012-09-05

Similar Documents

Publication Publication Date Title
PE20120563A1 (es) Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
AR094178A1 (es) Derivados de exendina-4 funcionalizada
AR112480A1 (es) Composiciones de glp-1 y sus usos
AR081200A1 (es) Formulaciones de insulina de accion prolongada
PE20190355A1 (es) Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo
TR201903610T4 (tr) Alfa-melanosit uyarici hormonlarin peptid analoglari.
AR098736A1 (es) Análogos del péptido exendina-4 como agonistas duales del receptor del glp-1 / gip (péptido similar al glucagón tipo 1 / polipéptido insulinotrópico dependiente de glucosa)
AR098737A1 (es) Agonistas duales del receptor de glp-1 / gip
HRP20110242T1 (hr) Formulacija s fuzijskim proteinom glp-1-fc
PE20241305A1 (es) Analogos de amilina
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
PE20142330A1 (es) Vacuna de peptido ch3 de ige
ECSP17085659A (es) Unidad de dosificación orodispersable que contiene un componente estetrol
AR096162A1 (es) Péptidos terapéuticos
AR079197A1 (es) Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas
CO2020008308A2 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
CU24043B1 (es) Hormona foliculoestimulante humana recombinante, composición farmacéutica que la comprende
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
MX2017003117A (es) Particula tipo virus de flavivirus.
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
AR114324A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
PE20131034A1 (es) El nuevo estable polietileno glicol conjugado de interferon alfa, representado por un isomero posicional
ES2538486T3 (es) Preparación de péptidos antigénicos contra el cáncer
AR068020A1 (es) Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal